Abstract 154P
Background
The Australian Pancreatic Screening study offers endoscopic ultrasound surveillance for individuals at increased risk of developing pancreatic cancer. Given 5-10% of pancreatic cancers are linked to genetic predisposition, all participants are required to undergo genetic counselling. We report on the genetic characteristics of this initial cohort from our institution.
Methods
This is a multicentre, prospective cohort study. Individuals with 2 or more family members with pancreatic cancer (including one of first-degree association) and/or those with a known genetic syndrome were defined as high-risk and eligible for study entry. Subjects aged between 40 and 80 years (or 10 years younger than the relative with pancreatic cancer) were included. The study was approved by the Austin Health Human Research Ethics Committee and the first participant consented in July 2013. Data was collected through participant completed questionnaires and review of medical records. All participants were seen by a Familial Cancer Clinic. Those with an indication for further genetic testing were offered gene panel tests. Indications that there may be an inherited predisposition to pancreatic cancer includes; a family history of breast and ovarian cancer, bowel cancer, melanoma, and chronic pancreatitis.
Results
121 participants were recruited from 96 families. In 12 out of 96 families there was a previously known high-risk germline mutation (6 BRCA2, 3 CDKN2A, 2 PALB2 and 1 STK11). 12 out of 84 families with no known mutation were offered genetic testing, either clinic or self-funded and 8 proceeded. Germline pathogenic mutations (Class 4 or 5) were detected in 3/8 families (37.5%), making the overall pick-up rate 3/84 (3.6%). Two families had a BRCA2 mutation and the other a CDKN2A mutation. In one family, where a pathogenic BRCA2 gene mutation was identified, cascade testing identified a further 3 relatives who carried the BRCA2 mutation. The CDKN2A carrier had a significant personal and family history of cutaneous melanoma. 1 participant had a PALB2 variant of uncertain significance.
Conclusions
In an enriched population, based on pedigree and increased genetic susceptibility, the rate of germ line mutations was high. Gene panels should be considered in selected patients undergoing high risk screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Health and Medical Research Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract